Holen Sie sich die Stockscreener-App
33.45
0.30%
-0.10
Handel nachbörslich:
33.45
Schlusskurs vom Vortag:
$33.55
Offen:
$33.56
24-Stunden-Volumen:
548.06K
Relative Volume:
0.63
Marktkapitalisierung:
$2.60B
Einnahmen:
$688.00K
Nettoeinkommen (Verlust:
$-170.19M
KGV:
-10.97
EPS:
-3.0495
Netto-Cashflow:
$-154.68M
1W Leistung:
+11.50%
1M Leistung:
+46.39%
6M Leistung:
+101.26%
1J Leistung:
+30.92%
1-Tages-Spanne:
$33.00
$34.06
1-Wochen-Bereich:
$28.16
$34.54
52-Wochen-Spanne:
$10.91
$34.54
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Firmenname
Spyre Therapeutics Inc
Sektor
Branche
Telefon
(617) 651-5940
Adresse
221 CRESCENT STREET, WALTHAM
Vergleichen Sie SYRE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
33.45 | 2.60B | 688.00K | -170.19M | -154.68M | -3.0495 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-26 | Eingeleitet | Deutsche Bank | Buy |
| 2025-04-08 | Eingeleitet | Leerink Partners | Outperform |
| 2025-03-18 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-04 | Eingeleitet | Wedbush | Outperform |
| 2024-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2024-05-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-03-01 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Eingeleitet | BTIG Research | Buy |
| 2023-12-11 | Eingeleitet | Guggenheim | Buy |
| 2023-12-11 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2019-03-21 | Eingeleitet | JP Morgan | Overweight |
| 2018-09-04 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-14 | Bestätigt | Needham | Buy |
Alle ansehen
Spyre Therapeutics Inc Aktie (SYRE) Neueste Nachrichten
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics (NASDAQ: SYRE) issues 20,300-share inducement stock options - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares - MarketBeat
Will Spyre Therapeutics Inc. (3920) stock see insider accumulationEarnings Overview Report & Fast Momentum Stock Entry Tips - Newser
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2%Still a Buy? - MarketBeat
Spyre Therapeutics CEO Turtle Cameron sells $435k in stock By Investing.com - Investing.com UK
Spyre Therapeutics: A New Era Unfolds? - timothysykes.com
A significant driver of top-line growth: Spyre Therapeutics Inc (SYRE) - Setenews
Spyre Therapeutics stock reaches 52-week high at 30.56 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock reaches 52-week high at 30.56 USD - Investing.com
Is Spyre Therapeutics Inc. (3920) stock at risk of policy regulation2025 Valuation Update & Fast Exit and Entry Trade Guides - Newser
Why Spyre Therapeutics Inc. stock is in analyst buy zone2025 AllTime Highs & Detailed Earnings Play Strategies - Newser
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating - MarketBeat
What is the fair value of Spyre Therapeutics Inc. stock nowRate Hike & Verified Momentum Stock Watchlist - Newser
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to “Buy” Rating - Defense World
Spyre Therapeutics (NASDAQ:SYRE) Sets New 52-Week High After Analyst Upgrade - Defense World
Can Spyre Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Jones Trading Upgrades Spyre Therapeutics (SYRE) - Nasdaq
SYRE Stock Upgraded by Jones Trading; New Price Target Set at $6 - GuruFocus
Spyre Therapeutics, Inc. $SYRE Shares Acquired by Franklin Resources Inc. - MarketBeat
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC - Defense World
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Geode Capital Management LLC - MarketBeat
Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential - Investing.com Canada
Nasdaq Composite Tracks Rising Biotech Momentum At Spyre Therapeutics - Kalkine Media
What analysts say about Spyre Therapeutics Inc 3920 stockFundamental Stock Analysis & Big Returns Low Cost - earlytimes.in
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
A Look at Spyre Therapeutics Inc (SYRE) Shares in the Recent Past Indicates Growth - Setenews
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week HighHere's What Happened - MarketBeat
Spyre Therapeutics stock hits 52-week high at 29.1 USD By Investing.com - Investing.com South Africa
Spyre Therapeutics stock hits 52-week high at 29.1 USD - Investing.com India
Why Spyre Therapeutics Inc. (3920) stock benefits from AI revolutionWeekly Market Outlook & Weekly Stock Performance Updates - newser.com
Can Spyre Therapeutics Inc. stock deliver strong Q4 earningsMarket Movers & Fast Entry High Yield Tips - newser.com
Is Spyre Therapeutics Inc. (3920) stock worth buying before Fed actionTrend Reversal & Daily Stock Momentum Reports - newser.com
Top investors say Spyre Therapeutics Inc (SYRE) ticks everything they need - Setenews
Earnings visualization tools for Spyre Therapeutics Inc. - newser.com
Will Spyre Therapeutics Inc. (3920) stock recover faster than industryJuly 2025 Patterns & Fast Entry and Exit Trade Plans - newser.com
Using data tools to time your Spyre Therapeutics Inc. exit2025 Top Gainers & Safe Entry Momentum Tips - newser.com
Why Spyre Therapeutics Inc. stock is seen as undervaluedTrend Reversal & Reliable Entry Point Trade Alerts - newser.com
Backtesting results for Spyre Therapeutics Inc. trading strategiesQuarterly Portfolio Review & Long-Term Safe Investment Plans - newser.com
Will Spyre Therapeutics Inc. (3920) stock announce special dividend2025 Earnings Impact & Accurate Intraday Trading Signals - newser.com
Is a relief rally coming for Spyre Therapeutics Inc. holdersQuarterly Investment Review & Free Reliable Trade Execution Plans - newser.com
What margin trends mean for Spyre Therapeutics Inc. stock2025 Geopolitical Influence & Verified Momentum Stock Watchlist - newser.com
Finanzdaten der Spyre Therapeutics Inc-Aktie (SYRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spyre Therapeutics Inc-Aktie (SYRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Turtle Cameron | Chief Executive Officer |
Nov 03 '25 |
Sale |
23.33 |
45,000 |
1,049,778 |
701,907 |
1.44%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):